AEON Biopharma, Inc.

AEON Biopharma, Inc. (ticker: AEON) is a clinical-stage biopharmaceutical company that completed its de-SPAC merger with Priveterra Acquisition Corp, a blank-check vehicle sponsored by Priveterra Holdings LLC that conducted its IPO in 2021. Operating in the therapeutics sector with a focus on botulinum toxin-based medicines, AEON is currently a publicly traded post-merger entity listed on NYSE American. The company filed an 8-K with the SEC on June 17, 2026, under accession number 0001837607-26-000046, reflecting a current-event disclosure. For full filing history, sponsor terms, and real-time SPAC analytics on AEON and hundreds of other transactions, sign up for complete data access at SpacDesk.